It is important to acknowledge that business considerations can sometimes influence decisions in the medical field. HCQ, being a generic drug, may have posed challenges in terms of profitability, which could potentially impact the attention and resources allocated to its research and development.
However, it's crucial to note that the presence of such business interests does not automatically indicate corruption or malicious intent on the part of healthcare organizations. While biases and conflicts of interest can exist, it's important to rely on solid scientific evidence and peer-reviewed studies to evaluate the safety and efficacy of treatments.
The opinions and experiences of frontline medical professionals who directly interact with patients are valuable, but they should be complemented with rigorous scientific research and expert consensus to ensure comprehensive decision-making and patient care.
Based on meta-analyses published since, it does not appear HCQ would have saved many lives. And its use (prophylactic or otherwise) may have proved problematic in many cases.